

REMARKS

In accordance with the above amendments, claims 135-144, 152-161 and 168-176 have been canceled and claims 183, 193, 194, 203 and 204 have been amended. Claims 183-211 remain under consideration in the present application. No claim has been allowed.

The undersigned and English representative, John S. Miles, PhD, wish to thank the Examiner for graciously enabling a three-way telephone interview on August 9, 2006 to clarify and discuss certain issues pertaining to the present application.

The claims stand provisionally rejected under the judicially created doctrine of obviousness-type double-patenting as being unpatentable over co-pending application Serial No. 10/842,850. By a paper of even date, co-pending application Serial No. 10/842,850 has been expressly abandoned. A copy of that paper is attached hereto as an Exhibit A. Accordingly, the Examiner is requested to withdraw the rejection based on double patenting.

In response to the Examiner's remarks in the Advisory Action of August 28, 2006 and issues raised in the Interview of August 9, 2006 (Interview Summary dated August 17, 2006), the applicants offer certain additional amendments and explanatory remarks for consideration.

With the cancellation of claims 1-182, only claims 183-211 remain in the present application.

As indicated, it is the applicant's intent that of all these claims require that both the lentiviral vector DNA and the xenogeneic polynucleotide be incorporated in the genome of all the claimed transgenic animals. This being the case, it is believed that the rejection of the claims under 35 USC § 102(e) based on Brinster et al (USPN 5,858,354) and Deboer et al (USPN 5,741,957) and the rejection of the claims under 35 USC § 102(b) based on Leder et al. (USPN 4,736,866) have been overcome. This is in accord with earlier discussions and for even stronger reasons in view of the present amendments discussed next.

Claims 183, 193, 194, 203 and 204 have been further amended to indicate that the polynucleotides are xenogeneic and that both the released lentiviral vector and the xenogeneic polynucleotide are incorporated into the genome. Thus, the claimed transgenic animals are required to contain both the lentiviral vector and the xenogeneic polynucleotide. Such transgenic animals are believed to be undisclosed in the art.

In the Advisory Action, claim 183 has been interpreted to encompass a cat infected with FIV where FIV can be found in the germ cells. As amended, claim 183 is believed to clearly distinguish over FIV-infected cats for several reasons.

Firstly, FIV-infected cats do not contain a xenogeneic polynucleotide. Rather, FIV only has any real existence in the cat population or when infecting cat cells and so no part of it

can be considered xenogeneic.

Secondly, FIV-infected cats would contain FIV principally in their T cells whereas the non-human transgenic vertebrate of claim 183 has the lentiviral vector and xenogeneic polynucleotide only in its testis.

References newly cited with the Interview Summary

The Examiner has cited Naldini et al (1996) Proc. Natl. Acad. Sci. USA 93, 11382-11388 with the Interview Summary. This paper discloses lentiviral vector injected into adult rat brains.

These rats contain lentiviral vector only in their brain. In contrast, the non-human vertebrate of claim 183 contains lentivirus (+ xenogeneic polynucleotide) in the testis only (and not in other tissues, including the brain). The non-human vertebrate of claim 185 contain lentivirus (+ xenogeneic polynucleotide) in substantially all somatic cells since the claim 185 animal has been bred from the claim 183 animal and transgenic progeny selected.

Thus, the transgenic animals of claims 183 and 185 are believed to distinguish over Naldini et al.

The Examiner has also cited Blömer et al (1997) J. Virol. 71, 6641-6649 with the Interview Summary. This paper discloses the localized transfer of a lentiviral vector into neurons of an adult rat.

As for Naldini et al (1996) discussed above, the lentiviral

vector is restricted to the adult neuron and there is no disclosure of an animal containing the lentiviral vector (+xenogeneic polynucleotide) only in the testis, as in claim 183, or of an animal in which substantially all somatic cells contain lentiviral vector (+xenogeneic polynucleotide).


Thus, the transgenic animals of claims 183 and 185 are believed to distinguish over Blömer et al.

The Examiner has also cited Jordan et al (1995) J. Virol. 69, 7328-7333 with the Interview Summary. This paper relates to FIV infection of cats.. Claims 183 and 185 are distinguished from this as discussed above.

It is believed, in view of the present amendments and explanatory remarks, that the present claims distinguish over all of the references of record. Accordingly, the Examiner is respectfully requested to enter this paper, reconsider his position and withdraw the present rejections and allow the claims.

Respectfully submitted,

NIKOLAI & MERSEREAU, P.A.



Thomas J. Nikolai for
C. G. Mersereau
Registration No. 26205
900 Second Avenue So.
Suite 820
Minneapolis, MN 55402
(612) 339-7461

CERTIFICATE OF FACSIMILE TRANSMISSION

I hereby certify that the foregoing Amendment in response to the Advisory Action of August 28, 2006, a copy of the Express Abandon document, Petition for a one-month extension of time, and a Transmittal Letter in application Serial No. 10/054,365, filed on November 12, 2001, of Carol W. Readhead et al, entitled "TRANSFECTION, STORAGE AND TRANSFER OF MALE GERM CELLS FOR GENERATION OF TRANSGENIC SPECIES & GENETIC THERAPIES" are being sent by facsimile transmission to: The Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on October 16, 2006.



Barbara L. Davis
on behalf of C. G. Mersereau
Attorney for Applicant

Date of Signature: October 16, 2006